Testing a decision aid for blood thinner choices after a heart attack
Tests a patient decision aid on blood thinner choices in acute coronary syndrome.
Plain-language title generated from the registry record
Registry title: DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid
Key facts
- Where
- Montreal, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in the coronary care unit at the Montreal Heart Institute who had an acute coronary syndrome and received a stent. They must have both high bleeding risk and high clot risk.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Acute coronary syndrome during the current hospital stay, treated with PCI and one or more coronary stents. High bleeding risk (PRECISE-HBR score) and high clot risk, both seen as equally important by the treating team.
Main reasons for not taking part
- Taking blood thinners (therapeutic anticoagulation)
- Heart surgery planned during the same hospital stay
- Earlier clot in a coronary stent
- Antiphospholipid syndrome or known thrombophilia
- Cannot take part in shared decision-making or does not understand spoken and written French or English
Read by machine on 9 November 2026.
Where in Canada
- Montreal Heart InstituteMontreal, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Montreal Heart Institute
- Trial code
- NCT07391358
- Record updated
- 5 February 2026
- Original description
Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at high thrombotic risk. In this population, several dual antiplatelet therapy (DAPT) strategies may be considered: (1) de-escalation of DAPT intensity after 1 to 3 months (switch from ticagrelor/prasugrel to clopidogrel), (2) shortening DAPT duration to 1 to 3 months followed by antiplatelet monotherapy, (3) 12-month clopidogrel-based DAPT, and (4) 12-month ticagrelor/prasugrel-based DAPT. Selecting the most appropriate DAPT strategy in this dual-risk context is complex, and clinical trial evidence is limited for this specific subgroup. In the absence of clear guideline recommendations to support decision-making for patients facing both elevated bleeding and thrombotic risks, structured shared decision-making support is needed.Read full original descriptionShow less
Dual Antiplatelet Therapy Strategy in High Bleeding Risk Patients Undergoing Complex Percutaneous Coronary Intervention Following Acute Coronary Syndrome: Second-Phase Beta Testing of a Patients Decision Aid
Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at high thrombotic risk. In this population, several dual antiplatelet therapy (DAPT) strategies may be considered: (1) de-escalation of DAPT intensity after 1 to 3 months (switch from ticagrelor/prasugrel to clopidogrel), (2) shortening DAPT duration to 1 to 3 months followed by antiplatelet monotherapy, (3) 12-month clopidogrel-based DAPT, and (4) 12-month ticagrelor/prasugrel-based DAPT. Selecting the most appropriate DAPT strategy in this dual-risk context is complex, and clinical trial evidence is limited for this specific subgroup. In the absence of clear guideline recommendations to support decision-making for patients facing both elevated bleeding and thrombotic risks, structured shared decision-making support is needed.
In this context, within research project 2025-3499 conducted with pharmacy residents, we developed a patient decision aid (PDA) designed to support shared decision-making by helping patients understand their risks, available options, and potential consequences, so they can express their preferences regarding antiplatelet therapy. The PDA aims to facilitate shared decisions by improving patients' understanding of benefits and harms and aligning choices with patient values. A preliminary version of the tool has already undergone alpha testing with a small group of internal users (physicians, pharmacists, and patient partners). The next step is beta testing, that is, real-world testing with the target population and clinicians to evaluate usability and acceptability in routine practice.
Inclusion: Adults aged 18 years or older; Hospitalized on the coronary care unit ward at the Montreal Heart Institute (MHI); Acute coronary syndrome (ACS) during the current episode of care, treated with PCI and placement of one or more coronary stents; High bleeding risk based on PRECISE-HBR score and high thrombotic risk, with both risks considered of comparable clinical importance by the treating medical team; Clinicians working in the MHI coronary care unit (cardiologists, medical residents, nurse practitioners, or pharmacists) who use the patient decision aid with one or more study participants.
Exclusion: Receiving therapeutic anticoagulation; Prior history of coronary stent thrombosis; Concurrent participation in another study (followed within another research protocol); Planned cardiac surgery during the same episode of care; Antiphospholipid syndrome or known thrombophilia; Unable to participate in shared decision-making; Unable to understand spoken and written French or English; Transferred from another center for reasons other than coronary angiography at MHI and expected to return to the referring center for ongoing care (i.e., "fly-in/fly-out" patients).